Jade Biosciences, Inc. Common Stock (JBIO) Stock Price
JBIOStock
$21.84+159.17%52W
Market Cap$1.39B
P/E—
PEG Ratio—
Div yield0.00%
Beta1.57
JBIO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)36.26%
Price vs S&P 500 (4W)5.22%
VGM Score58.16
Indicated Dividend Yield (Annual)0.00%
JBIO Earnings Surprise History
Q2 25-0.86est. -0.48
Q3 25-0.48est. -0.67
Q1 26-0.57est. -0.48
Q2 26-0.76est. -0.54
JBIO Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.44
4.44
4.41
4.41
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
JBIOJade Biosciences, Inc. Common Stock | — | — | C | $21.84 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Jade Biosciences, Inc. Common Stock
Jade Biosciences develops immunotherapies targeting autoimmune diseases using antibody-based approaches. The company's lead candidate, JADE-001, targets the APRIL pathway for IgA nephropathy treatment and is advancing toward clinical-stage development. Jade maintains two additional antibody programs in preclinical development and was founded using technology licensed from Paragon Therapeutics.